Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Dynavax Technologies Corporation's Stock Gained 14.5% In March

By George Budwell - Apr 9, 2016 at 3:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Heplisav-B's fate is now in the hands of the FDA.

DVAX Chart

DVAX data by YCharts.

What: Shares of Dynavax Technologies (DVAX -0.09%) popped 14.5% last month, according to data from S&P Global Market Intelligence. The underlying catalyst behind this move seems to be the company's announcement that the FDA accepted Heplisav-B's Biologics License Application (BLA) for review as a potential vaccine against hepatitis B infection in adults 18 years of age and older. 

So what: Heplisav is expected to compete directly against GlaxoSmithKline's (GSK -1.06%) Engerix-B, which has been the standard of care against hepatitis B since its approval in 1989. Heplisav's late-stage study data showed that Dynavax's experimental vaccine candidate produced greater seroprotection using fewer doses than Engerix-B, putting it in prime position to capture a significant portion of the current $270 million hepatitis B market inside the United States, if approved.  

Image source: Wikimedia Commons. 

Now what: According to the press release, the FDA assigned a target action date to Heplisav's BLA of Sept. 15, 2016, implying that Dynavax could have its first commercial product on the market before year's end. While anything is possible when it comes to regulatory reviews, Dynavax seems to have met the FDA's stated requirements in terms of safety with Heplisav's latest pivotal trial -- that is, unless there is an unexpected bombshell hiding in the full data set.  

Barring a black swan event, though, Glaxo seems like it will have an interesting decision to make later this year regarding the future of its hepatitis B franchise. Although the drugmaker does have some intriguing early stage candidates in development for hepatitis B, Heplisav stands a good chance at becoming the market share leader within a few short years. In fact, Dynavax's management believes Heplisav could greatly expand the U.S. market to perhaps $600 million a year in annual sales, given its effectiveness in hard-to-treat sub-populations like diabetics. 

All told, Dynavax and Glaxo's respective shareholders may want to pay close attention to Heplisav's forthcoming regulatory review, as this experimental vaccine could make a major impact on the entire hepatitis B market going forward. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
$11.78 (-0.09%) $0.01
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
$44.49 (-1.06%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.